NeoGenomics (NASDAQ: NEO) reported Q2 EPS of $0.05, $0.02 better than the analyst estimate of $0.03. Revenue for the quarter came in at $202 million versus the consensus estimate of $196.99 million.

GUIDANCE:

NeoGenomics sees FY2026 revenue of $802-806 million, versus the consensus of $800.4 million.

For earnings history and earnings-related data on NeoGenomics (NEO) click here.